Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care. APPENDIX 2: Case Studies Site Selection Criteria

07/09/2020

APPENDIX 2. CASE STUDIES SITE SELECTION CRITERIA

IBM Watson Health

July 2020

DISCLAIMER: The opinions and views expressed in this report are those of the authors. They do not reflect the views of the Department of Health and Human Services, the contractor or any other funding organization. This report was completed and submitted on January 7, 2019.

 

TABLE OF CONTENTS

ACRONYMS

SITE SELECTION CRITERIA

  • TABLE A2-1: Criteria to Consider as Part of Case Study Selection

 

ACRONYMS

The following acronyms are mentioned in this appendix.

CJS Criminal Justice System
 
MAT Medication-Assisted Treatment
 
OUD Opioid Use Disorder
 
SUD Substance Use Disorder

 

SITE SELECTION CRITERIA

Based on input from ASPE at the kickoff meeting, the literature review, and discussion with key informants and internal subject matter experts, we propose the criteria listed in Table A2-1 to be considered as part of case study site selection. We do not believe that any given size or length of time in operation, for example, should be determinative. Rather, these are characteristics to take into account as we consider potential sites in order to have a balanced group to study.

TABLE A2-1. Criteria to Consider as Part of Case Study Selection
Criteria Sub-Criteria to Consider
Structural
  • Size
  • Provider mix
  • Reimbursement innovations
  • Time in operation
  • State Medicaid expansion status
Programmatic
  • Models of specialty SUD treatment
  • Evidence-based or other treatments
  • Medication used for OUD MAT
  • Models of psychosocial support used
  • Integration of supports such as housing, childcare, transportation
  • Integration or coordination of SUD, mental health, and/or physical health care
  • Focus on OUD vs. other SUDs
  • Telehealth as a promoter of treatment continuity
  • Integrated treatment
Population
  • Geographic factors such as region, rurality, opioid prevalence
  • Diversity of populations served
  • Special populations (material and child; CJS, homeless)
Outcomes
  • Higher retention in treatment
  • Patient outcomes (e.g., reduced overdoses, abstinence, functioning)
Other
  • Evidence from other evaluations
  • Other criteria to be determined